Medivirs CMO to BioStock: “Our new clinical data are very encouraging”

Medivir presents the first clinical data with fostrox + Lenvima at the ASCO GI scientific congress, showing further improved clinical benefit vs previous interim updates from the ongoing phase Ib/IIa study in advanced hepatocellular carcinoma. According to the company, the data supports the planning for a pivotal phase IIb study in 2024. BioStock reached out to Pia Baumann, Medivir’s CMO, to learn more about the new data.

Read the full interview with Pia Baumann at biostock.se:

https://www.biostock.se/en/2024/01/medivirs-cmo-our-new-clinical-data-are-very-encouraging/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/